Trial Profile

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Participants With Relapsed/Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ISB 1442 (Primary)
Indications Acute myeloid leukaemia; Multiple myeloma; Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Ichnos Sciences

Most Recent Events

17 Jan 2025 Status changed from recruiting to discontinued.
05 Nov 2024 According to an Ichnos Glenmark Innovation media release, the company to present results from this trial at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.
12 Dec 2023 Initial results (n=10) of dose-escalation portion of this trial presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com